Wockhardt
Market cap ₹32,935 Cr
- P/E
- 80.36
- Day range
- ₹2,005.00 – ₹2,065.00
- 52-week range
- ₹1,086.70 – ₹2,422.30
- Volume
- 7.26 L
- Open
- ₹2,018.30
- Prev close
- ₹2,008.90
Latest results · Q2 FY27(consolidated)Revenue ₹969 Cr+23.9%Profit ₹73 Cr-11.0%Margin 7.5%YoY vs the same quarter last year
No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.
WOCKPHARMA in NSE indices and F&O
Research profile
Composite 48 / 100Factor percentiles
Derived metrics
- Earn. yield
- 1.2%
- Graham no.
- ₹420.62
- vs Graham
- -79.2%
- ROE ÷ P/B
- 0.7%
- 12-1 mom.
- +45.7%
- Return / vol
- 1.01
- Magic Formula
- #592
- Piotroski
- 5/6
- FCF yield
- 0.1%
Appears in 5 scans
Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.
Peer comparison
All 68 in Pharma| Company | M-cap | P/E | P/B | ROE | ROCE | OPM | D/E | Sales YoY |
|---|---|---|---|---|---|---|---|---|
| Sun PharmaSUNPHARMA | ₹4.49 L Cr | 40.95 | 5.03 | 14.8% | 21.0% | 29.0% | 0.04 | +11.9% |
| Divi's LaboratoriesDIVISLAB | ₹2.93 L Cr | 87.19 | 16.88 | 16.2% | 22.0% | 43.0% | 0.00 | +35.4% |
| Torrent PharmaTORNTPHARM | ₹1.75 L Cr | 77.88 | 9.67 | 26.8% | 15.0% | 33.0% | 0.77 | +50.8% |
| Apollo HospitalsAPOLLOHOSP | ₹1.27 L Cr | 56.40 | 11.55 | 22.6% | 17.0% | 16.0% | 0.77 | +23.0% |
| Laurus LabsLAURUSLABS | ₹1.25 L Cr | 93.72 | 19.82 | 18.2% | 18.0% | 34.0% | 0.43 | +33.5% |
| Zydus LifesciencesZYDUSLIFE | ₹1.20 L Cr | 28.72 | 4.32 | 20.1% | 21.0% | 24.0% | 0.50 | +29.2% |
| Dr. Reddy's LabsDRREDDY | ₹1.17 L Cr | 41.63 | 2.97 | 11.6% | 13.0% | 20.0% | 0.19 | -1.5% |
| WockhardtWOCKPHARMA | ₹32,935 Cr | 80.36 | 6.34 | 4.3% | 8.0% | 18.0% | 0.43 | +23.9% |
| Sector median | ₹24,603 Cr | 43.68 | 5.46 | 15.1% | 17.0% | 24.0% | 0.17 | +22.7% |
Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.
Latest news
Updated 1d agoHeadlines about Wockhardt from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.
Key metrics
- P/E (TTM)
- 81.7
- Price / Book
- 6.39
- ROE (FY26)
- 4.3%
- ROCE (latest year)
- 8%
- Dividend yield
- 0.00%
Moving averages (NSE)
- 20-day
- ₹1,931.67
- Price above
- 50-day
- ₹2,041.76
- Price below
- 200-day
- ₹1,735.87
- Price above
Charts & trends
From company filings. Amounts in ₹ crore.
Revenue, profit & margin - quarterly
₹ crore; a loss shows red. Operating margin below, same periods.
- Revenue
- Net profit
Operating margin
Who owns the company
% of equity by quarter, latest Sept 2026
- Promoter
- Public
- DII
- FII
- Government
Cash flows
Where cash came from and went, by fiscal year (₹ crore)
- Operating
- Investing
- Financing
- Free cash flow
Return on equity
Net profit over shareholders' equity, by fiscal year
Equity vs debt
Shareholders' equity against borrowings (₹ crore); the ratio below, same years.
- Equity
- Debt
Debt to equity
Dividends per share
₹ by fiscal year of the ex-date; the latest year runs to date.
Financial statements
| Line item | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 701 | 700 | 739 | 809 | 721 | 743 | 738 | 782 | 888 | 965 | 929 | 969 |
| YoY Sales growth | — | — | — | — | — | — | 0 | -3 | — | — | — | — |
| Expenses | 664 | 759 | 648 | 699 | 593 | 679 | 666 | 604 | 711 | 740 | 737 | 796 |
| Operating Profit | 37 | -59 | 91 | 110 | 128 | 64 | 72 | 178 | 177 | 225 | 192 | 173 |
| OPM % | 5% | -8% | 12% | 14% | 18% | 9% | 10% | 23% | 20% | 23% | 21% | 18% |
| Other Income | 8 | 10 | 30 | 9 | 8 | 15 | -77 | 21 | 15 | 67 | 31 | 11 |
| Interest | 77 | 73 | 73 | 73 | 60 | 48 | 48 | 55 | 60 | 50 | 52 | 56 |
| Depreciation | 55 | 58 | 54 | 55 | 55 | 53 | 56 | 53 | 65 | 53 | 55 | 55 |
| Profit before tax | -87 | -180 | -6 | -9 | 21 | -22 | -109 | 91 | 67 | 189 | 116 | 73 |
| Tax % | -1% | -2% | 167% | 78% | 5% | 105% | -1% | 10% | 9% | 13% | 8% | 0% |
| Net Profit | -86 | -177 | -16 | -16 | 20 | -45 | -108 | 82 | 61 | 164 | 107 | 73 |
| EPS in Rs | ₹-5.76 | ₹-11.02 | ₹-0.91 | ₹-1.43 | ₹0.86 | ₹-1.54 | ₹-5.54 | ₹4.80 | ₹3.63 | ₹10.22 | ₹6.52 | ₹4.86 |
From company filings, updated 18 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.
Working-capital cycle
-60 days since Mar 2021
+30 days since Mar 2021
-41 days since Mar 2021
+11 days since Mar 2021
+168 days since Mar 2021
Strengths, risks & growth
Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). [1]
Strengths
None flagged by the checklist.
Risks
- Stock is trading at 6.33 times its book value
- The company has delivered a poor sales growth of 4.49% over past five years.
- Company has a low return on equity of -1.43% over last 3 years.
- Promoter holding has decreased over last 3 years: -5.81%
Compounded Sales Growth
- 10 Years
- -3%
- 5 Years
- +4%
- 3 Years
- +8%
- TTM
- +26%
Compounded Profit Growth
- 10 Years
- +1%
- 5 Years
- -19%
- 3 Years
- +43%
- TTM
- +629%
Stock Price CAGR
- 10 Years
- +12%
- 5 Years
- +38%
- 3 Years
- +83%
- 1 Year
- +47%
Return on Equity
- 10 Years
- -2%
- 5 Years
- -3%
- 3 Years
- -1%
- Last Year
- +6%
Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.
Shareholding pattern
| Holder | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 | Change |
|---|---|---|---|---|---|
| Promoter | 49.09% | 49.09% | 49.09% | 49.33% | +0.24 pp |
| FII | 7.00% | 7.09% | 7.23% | 7.02% | -0.21 pp |
| DII | 10.55% | 10.96% | 9.24% | 9.00% | -0.24 pp |
| Government | 0.02% | 0.04% | 0.02% | 0.01% | -0.01 pp |
| Public | 33.36% | 32.84% | 34.44% | 34.64% | +0.20 pp |
Filed with NSE for Sept 2026: promoters 49.32%, public 50.68%
Analysts & fund holdings
Who holds the shares, quarter by quarter
Mutual funds 5.99% (-0.80 pp)- Promoters49.3%
- Foreign institutions7.0%
- Mutual funds6.0%
- Insurance1.9%
- Other domestic institutions1.1%
- Retail19.2%
- Others15.5%
| Fund | % of company | % of fund | 3-month change |
|---|---|---|---|
| Tata Small Cap Fund | 1.22% | 3.38% | +0.13 pp |
| HSBC Small Cap Fund | 0.69% | 1.30% | -0.00 pp |
| Tata Large & Mid Cap Fund | 0.57% | 2.70% | +0.27 pp |
| Invesco India Contra Fund | 0.38% | 0.65% | +0.01 pp |
| Bandhan Small Cap Fund | 0.30% | 0.28% | -0.07 pp |
Scorecard
- Performance
- Avg
- Valuation
- High
- Growth
- Low
- Profitability
- High
- Entry point
- Avg
- Red flags
- Low
Analyst coverage, holdings and scorecard from market data; not a recommendation by Rajat Finance.
Risk & trend
From 291 daily sessions to 17 Nov 2026.
Risk
- Volatility (1Y)
- 49.6%
- Downside volatility
- 38.9%
- Worst 5% of days
- 3.9%
- Average of that tail
- 6.1%
- Max drawdown (1Y)
- 29.7%
- Below its peak
- 13.8%
Against the market
- Beta vs Nifty 50
- 0.97
- Correlation
- 0.27
- Relative strength (3M)
- -0.2%
- ATR (14)
- 3.8%
Return
- Return 1M
- +3.1%
- Return 3M
- +3.9%
- Return 6M
- +30.0%
- Return 1Y
- +50.2%
- vs 200-day average
- +15.7%
Momentum
- RSI (14)
- 53.2
- MACD histogram
- 17.92
- Stochastic %K
- 71.9
- ADX (14)
- 18.0
- +DI / −DI
- 22.0 / 19.4
- Money flow index
- 57.2
Participation
- Delivery (20d avg)
- 37.5%
- vs its 60-day baseline
- -0.4 pts
- Volume vs 20-day
- -1.0σ
- Close vs day's VWAP
- -0.7%
- 52-week position
- 74 / 100
These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.
Financial quality
From consolidated statements to 30 Sept 2026.
Piotroski F-Score
5 of 6 tested
- Return on assets positive — passed
- Operating cash flow positive — not testableno cash flow statement for this period
- Return on assets improving — passed
- Cash flow exceeds profit — not testableneeds cash flow and profit against assets
- Debt to assets falling — failed
- Current ratio improving — passed
- No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
- Operating margin improving — passed
- Asset turnover improving — passed
- Free cash flow
- ₹26 Cr
- FCF yield
- 0.1%
- Cash conversion
- 1.96
- Accruals ratio
- -0.022
- Net debt
- ₹1,908 Cr
- Net debt / equity
- 0.37
- EV / sales
- 9.21
- Capex intensity
- 10.8%
- Revenue CAGR
- 19.3%
Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.
Corporate actions
- otherNot available — not reported in this filing
Annual General Meeting
21 Jun 2024ex-date - otherNot available — not reported in this filing
Annual General Meeting
7 Aug 2023ex-date - rightsNot available — not reported in this filing
Rights 3:10@ Premium Rs 220 Per Share
8 Mar 2022ex-date - otherNot available — not reported in this filing
Annual General Meeting
23 Jul 2021ex-date - otherNot available — not reported in this filing
Annual General Meeting
24 Jul 2020ex-date - otherNot available — not reported in this filing
Annual General Meeting
2 Aug 2019ex-date - otherNot available — not reported in this filing
Annual General Meeting
25 Jul 2018ex-date - otherNot available — not reported in this filing
Annual General Meeting
24 Jul 2017ex-date - dividend₹10.00
Interim Dividend Rs 10/- Per Share (Purose Revised)
17 Nov 2016ex-date - otherNot available — not reported in this filing
Annual General Meeting
4 Aug 2016ex-date - otherNot available — not reported in this filing
Annual General Meeting
3 Sept 2015ex-date - dividend₹20.00
Interim Dividend - Rs 20/- Per Share
13 Nov 2014ex-date - otherNot available — not reported in this filing
Annual General Meeting
4 Sept 2014ex-date - dividend₹5.00
Interim Dividend - Rs 5/- Per Share
17 Feb 2014ex-date - dividend₹5.00
Interim Dividend Rs.5/- Per Share
7 Nov 2013ex-date - dividend₹5.00
Annual General Meeting / Dividend Rs.5 Per Share
22 Aug 2013ex-date - otherNot available — not reported in this filing
Annual General Meeting
3 Sept 2012ex-date - otherNot available — not reported in this filing
Annual General Meeting
30 Aug 2011ex-date - otherNot available — not reported in this filing
Annual General Meeting
8 Sept 2010ex-date - otherNot available — not reported in this filing
Annual General Meeting
19 Jun 2009ex-date
Company announcements
Pursuant to Regulation 30 of SEBI LODR Regulations, 2015 read with Schedule III thereto, we wish to inform you that Mr. Vinesh Kumar Jairath (DIN: 00391684) has completed his second consecutive ....
Please refer the attachment.
Appointment of Mr. Sumit Garg as Chief Digital & Information Officer as Senior Management Personnel of the Company.
Please refer the attachment.
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of directors at its meeting held today, i.e. 2nd November, 2026, inter-alia, ....
Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company, at its meeting ....
We wish to inform that Share Allotment Committee of Board of Directors of the Company has allotted 20000 equity shares of face value of Rs 5 each on 27th October, 2026 pursuant to exercise ....
Wockhardt Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve Pursuant to Regulation 29(1) of SEBI ....
Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (LODR) Regulations, 2015, we enclose herewith a copy of newspaper advertisement regarding the opening of special ....
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please find attached the Certificate received from MUFG Intime India Private Limited, Registrar and ....
The Trading Window for dealing in the equity shares of the Company will be closed from 1st October, 2026 until 48 hours after the declaration of Unaudited financial results for quarter ....
Pursuant to Regulation 30 (read with Part A of Schedule III) of SEBI (LODR) Regulations 2015, we wish to inform you that the Company is in receipt of an Adjudication Order passed by Commissioner ....
Pursuant to Regulation 30 read with Schedule III Part A Para A of the SEBI (LODR) Regulations, 2015, we enclose herewith a copy of newspaper advertisement published today i.e. 25th August, ....
Please find enclosed herewith Scrutinizer's Report on the combined voting results of remote e-voting and e-voting during the 27th AGM of the Company
Pursuant to Regulation 30 read with Para A of Part A of Schedule III of SEBI (LODR) Regulations, 2015, the Proceedings of the 27th AGM of the Company
Filed with BSE (scrip 532300); the last 45 days. Documents open at bseindia.com.
SEBI filings & orders
From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.
Regulatory orders
- Adjudication order
Adjudication order in respect of Crosseas Capital Services Ltd in the matter of trading in the Scrip of Wockhardt Ltd
31 Jul 2023Read on SEBI - Adjudication order
Adjudication Order in respect of three entities in the matter of Wockhardt Limited
31 Jul 2023Read on SEBI - Final order
Final Order in the matter of Wockhardt Ltd.
19 Jun 2023Read on SEBI - Settlement order
Settlement Order in respect of four entities in the matter of Wockhardt Limited
22 May 2023Read on SEBI - Settlement order
Settlement Order in respect of Vijay Khetan in the matter of Wockhardt Limited
2 Mar 2023Read on SEBI
Documents
Annual reports
Earnings calls
- Jun 2026TranscriptSlides
- Jun 2025TranscriptSlides
- Jun 2025Slides
- Feb 2025Slides
- Oct 2024Slides
- Feb 2024Slides
Credit ratings
- Rating update · 21 May from icra
- Rating update · 26 Aug 2025 from icra
- Rating update · 30 Aug 2024 from care
- Rating update · 3 Jul 2024 from fitch
- Rating update · 15 May 2024 from icra
- Rating update · 10 Oct 2023 from fitch
Documents open at BSE or the rating agency that issued them.
Sourced from the company's NSE XBRL filing dated 3 Nov 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.
Wockhardt: common questions
Answered from the figures on this page.